1. Home
  2. IPSC vs IDE Comparison

IPSC vs IDE Comparison

Compare IPSC & IDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Century Therapeutics Inc.

IPSC

Century Therapeutics Inc.

HOLD

Current Price

$2.33

Market Cap

189.7M

Sector

Health Care

ML Signal

HOLD

Logo Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

IDE

Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

HOLD

Current Price

$13.37

Market Cap

187.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IPSC
IDE
Founded
2019
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
189.7M
187.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
IPSC
IDE
Price
$2.33
$13.37
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$3.50
N/A
AVG Volume (30 Days)
2.9M
33.5K
Earning Date
03-18-2026
01-01-0001
Dividend Yield
N/A
8.83%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$113,337,000.00
N/A
Revenue This Year
$1,590.09
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4122.69
N/A
52 Week Low
$0.34
$8.61
52 Week High
$2.71
$10.46

Technical Indicators

Market Signals
Indicator
IPSC
IDE
Relative Strength Index (RSI) 65.56 84.94
Support Level $2.08 $12.33
Resistance Level $2.71 $13.26
Average True Range (ATR) 0.33 0.13
MACD 0.03 0.06
Stochastic Oscillator 67.24 92.41

Price Performance

Historical Comparison
IPSC
IDE

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

Share on Social Networks: